Zymeworks Joins Nasdaq Biotechnology Index
December 16, 2023
🌥️Trending News
Zymeworks Inc ($NASDAQ:ZYME). has just joined the Nasdaq Biotechnology Index, making it one of the few Canadian biotechnology companies to become part of this prestigious index. Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. It is committed to developing highly differentiated product candidates with the potential to address unmet medical needs, and is focused on creating therapies to fight cancer and autoimmune diseases. The company’s proprietary Azymetric™ platform is used to develop novel therapeutic options that are designed to have long-term efficacy and safety by combining two or more mechanisms of action.
Zymeworks has a diverse pipeline of candidates in clinical and preclinical development and is collaborating with some of the world’s top pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Janssen, Merck and Pfizer, in order to bring the best treatments to patients. Investors can now benefit from a growing portfolio of innovative therapeutics that have the potential to make a real difference in the lives of people living with serious illnesses.
Market Price
On Friday, ZYMEWORKS INC joined the Nasdaq Biotechnology Index, as its stock opened at $9.1 and closed at $9.1, an increase of 0.9% from its previous closing price of $9.0. This marks a major milestone for the biopharmaceutical company, which is dedicated to developing next-generation breakthroughs in the field of antibody engineering and protein therapeutics. The new listing on the index is testament to the company’s ever-growing success and demonstrates its commitment to implementing innovative and impactful treatments for cancer and other diseases. Going forward, ZYMEWORKS INC is hopeful that its increased visibility on the Nasdaq Biotechnology Index will further strengthen its position in the industry and help it make strides toward its mission of creating meaningful solutions for patients around the world. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zymeworks Inc. More…
| Total Revenues | Net Income | Net Margin |
| 461.58 | 205.01 | 44.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zymeworks Inc. More…
| Operations | Investing | Financing |
| 195.1 | -227.98 | 30.86 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zymeworks Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 556.37 | 132.02 | 6.25 |
Key Ratios Snapshot
Some of the financial key ratios for Zymeworks Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 163.8% | – | 44.4% |
| FCF Margin | ROE | ROA |
| 41.6% | 29.3% | 23.0% |
Analysis
As GoodWhale, we have conducted an in-depth analysis of ZYMEWORKS INC‘s wellbeing. Our Star Chart has revealed that ZYMEWORKS INC is strong in asset, growth, and profitability, yet weak in dividends. Additionally, our health score for their cashflows and debt is 6/10, indicating that ZYMEWORKS INC is likely to sustain future operations in times of crisis. After further analysis, we have classified ZYMEWORKS INC as a ‘gorilla’ – a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. This makes ZYMEWORKS INC an attractive option for investors who are looking for long-term growth and stability. Not only will they benefit from the company’s current performance, but they will also be able to trust in its ability to weather any storm. More…
Peers
It is one of several innovative companies in the space, including Alaunos Therapeutics Inc, BerGenBio ASA, and Vaxil Bio Ltd, that are on the cutting edge of medical research. Each of these companies are focused on developing new solutions to improve patient care and outcomes.
– Alaunos Therapeutics Inc ($NASDAQ:TCRT)
Alaunos Therapeutics Inc is a biopharmaceutical company dedicated to the development of innovative treatments for central nervous system disorders. The company has a market cap of 122.82M as of 2023 and a Return on Equity of -61.16%. This suggests that the company’s equity investments are not generating adequate returns to reward its investors. Despite this, Alaunos Therapeutics Inc has seen a steady increase in its market capitalization, suggesting that investors are confident in the potential of its products and services. The company’s development of innovative treatments for central nervous system disorders could be a major factor driving its market cap growth.
– BerGenBio ASA ($BER:7BG)
BerGenBio ASA is a specialized biopharmaceutical company that focuses on discovering, developing, and commercializing first-in-class therapies to treat serious diseases. The company’s market cap as of 2023 is 46.2 million, indicating a relatively small market size compared to its peers. This small market size is reflective of the company’s Return on Equity (ROE), as it was -93.4% in 2023. This low ROE indicates that the company is not generating sufficient profits relative to its invested capital. As a result, BerGenBio ASA is heavily reliant on external financing which can be difficult to obtain due to its low ROE.
– Vaxil Bio Ltd ($TSXV:VXL)
Vaxil Bio Ltd is a biotechnology company that focuses on the development and commercialization of novel immunotherapy treatments for cancer and infectious diseases. With a market capitalization of 2.74M as of 2023, the company is relatively small but has tremendous potential for growth over the next few years. The company also has a negative return on equity of -31.57%, indicating that it has had difficulty in generating profits from its investments. Despite this, the company has seen strong revenue growth and is increasingly being seen as a viable player in the biotech industry. With continued investment, Vaxil Bio Ltd could become a major player in the industry.
Summary
Zymeworks Inc (ZYME) is a publicly traded biotechnology company that develops and commercializes biotherapeutic products for cancer and other diseases. This addition to the index is particularly exciting as it indicates strong investor confidence in the company. ZYME has seen its share price rise steadily over the past year, and its share price has outperformed that of the broader Nasdaq. The company has a strong portfolio of products in its pipeline and has recently made advances in its antibody-drug conjugate technology.
Looking ahead, the company is likely to see strong growth in both its revenue and earnings as its products reach the market. With its inclusion to the Nasdaq Biotechnology Index, investors have an opportunity to capitalize on ZYME’s potential for long-term growth.
